

Registered No: 13737726

Apollo AP21 Limited

Annual Report and Accounts

31 December 2024

FRIDAY



AEAF7T

A13

05/09/2025

#116

COMPANIES HOUSE

Corporate Information

Directors:

Dr Richard Mason
Dr Richard Butt
Jamie Heath

Registered Office:

3rd Floor, 22 Station Road
Cambridge
CB1 2JD
United Kingdom

Company number:

13737726

Contents

	Page
Report of the Directors	3 - 4
Statement of Comprehensive Income	5
Statement of Financial Position	6
Statement of Changes in Equity	7
Notes to the Financial Statements	8 - 11

Apollo AP21 Limited

Report of Directors for the year ended 31 December 2024

The directors present their report and the financial statements of the company for the year ended 31 December 2024.

PRINCIPAL ACTIVITY

The Company is a special purpose vehicle ("SPV") advancing a potentially transformative therapeutic program into clinical development and ultimately into patient treatment.

DIRECTORS

The directors who served during the year and to the date of this report were:

Dr Richard Mason
Dr Richard Butt
Jamie Heath (appointed 7 January 2025)

DIRECTORS' INDEMNITY ARRANGEMENTS

During the year the Company purchased Directors' and Officers' liabilities insurance, which remains in force at the date of this report.

GOING CONCERN AND FINANCIAL RISK MANAGEMENT

Apollo AP21 Limited is reliant on funding received from its parent company Apollo Therapeutics Group Limited ("the Group") and has no other external source of income. Apollo AP21 Limited is an SPV of its direct parent Apollo Therapeutics Limited which is the main treasury entity of the Group and accordingly the directors have assessed the Group's ability to continue to fund Apollo Therapeutics Limited, and in turn Apollo AP21 Limited.

The directors believe that the Group will have sufficient funding to continue its operations for at least twelve months from the date of approval of these financial statements. Accordingly, the accounts have been prepared on the going concern basis.

The Group expects, over the coming years, to finance its operations through a combination of cash on hand and private or public equity financings. The Groups failure to raise capital as and when needed would have a negative effect on our financial condition and our ability to execute our business strategy. Based on the year end cash position and forecast future cashflows, the directors have considered scenarios where costs within the directors' control can be delayed or deferred to ensure that the Group has sufficient funding to continue its operations for a period of at least 12 months from the date of approval of these financial statements. The base case is built on the assumption of nil revenue generation.

KEY PERFORMANCE INDICATORS

The directors have monitored the performance of the Company with particular reference to the key performance indicator being research and development expenditure and development timeline of projects. The directors are satisfied with the project developments in 2024 with projects progressing along planned timelines.

DIRECTORS' RESPONSIBILITIES FOR THE FINANCIAL STATEMENTS

The directors are responsible for preparing the Report of the Directors and the financial statements in accordance with applicable law and regulations.

Company law requires the directors to prepare financial statements for each financial period. Under that law, the directors have elected to prepare the financial statements in accordance with United Kingdom Generally Accepted Accounting Practice and applicable law including FRS 101 'Reduced Disclosure Framework'. Under company law the directors must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs and of the profit or loss of the Company for that period. In preparing these financial statements, the directors are required to:

- select suitable accounting policies and then apply them consistently;
- make judgements and accounting estimates that are reasonable and prudent;
- state whether applicable UK Accounting Standards have been followed, subject to any material departures disclosed and explained in the financial statements;
- prepare the financial statements on a going concern basis unless it is inappropriate to presume that the Company will continue in business.

Apollo AP21 Limited

Report of Directors for the year ended 31 December 2024 (continued)

DIRECTORS' RESPONSIBILITIES FOR THE FINANCIAL STATEMENTS (continued)

The directors are responsible for keeping adequate accounting records that are sufficient to show and explain the Company's transactions and disclose with reasonable accuracy at any time the financial position of the Company and to enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the Company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

The directors confirm that:

- so far as each director is aware, there is no relevant audit information of which the Company's auditor is unaware; and
- the directors have taken all steps that they ought to have taken as directors to make themselves aware of any relevant audit information and to establish that the auditor is aware of that information.

AUDIT EXEMPTION

For the year ended 31 December 2024, the Company was entitled to exemption from audit under s479A of the Companies Act 2006 relating to subsidiary companies.


Director's responsibilities in respect of audit exemption:

- The members have not required the Company to obtain an audit of its accounts for the year in question in accordance with s476 of the Companies Act 2006.
- The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of accounts.

SMALL COMPANIES EXEMPTION

In preparing this report, the directors have taken advantage of the small companies exemptions provided by section 415A of the Companies Act 2006.

Approved by the Board of Directors and signed on behalf of the Board.



Dr Richard Mason
Director

September 3, 2025

Apollo AP21 Limited

Statement of Comprehensive Income

for the year ended 31 December

	Notes	2024 \$'000	2023 \$'000
Revenue		—	—
Cost of sales		—	—
Gross profit		—	—
Administrative expenses		(5)	(17)
Research and development expenses		(373)	(952)
Effects of foreign exchange		(2)	3
Operating loss	4	(380)	(966)
Interest received		—	—
Loss before tax		(380)	(966)
Tax	6	(24)	(8)
Loss for the period		(404)	(974)
Total comprehensive loss for the period		(404)	(974)

The notes on pages 8 - 11 are an integral part of these financial statements.

Apollo AP21 Limited

Statement of Financial Position

as at 31 December

	Notes	2024 \$'000	2023 \$'000
Current assets			
Trade and other receivables	7	292	301
Tax receivable	6	33	28
Total current assets		325	329
Total assets		325	329
Liabilities			
Current liabilities			
Trade and other payables	8	(2,709)	(2,309)
Total current liabilities		(2,709)	(2,309)
Total liabilities		(2,709)	(2,309)
Net Liabilities		(2,384)	(1,980)
Equity			
Called up share capital	9	—	—
Retained earnings		(2,384)	(1,980)
Total equity		(2,384)	(1,980)

The notes on pages 8 - 11 are an integral part of these financial statements.


AUDIT EXEMPTION

For the year ended 31 December 2024, the Company was entitled to exemption from audit under s479A of the Companies Act 2006 relating to subsidiary companies.

Director's responsibilities in respect of audit exemption:

- The members have not required the Company to obtain an audit of its accounts for the year in question in accordance with s476 of the Companies Act 2006.
- The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of accounts.

The financial statements were approved and authorised for issue by the Board of Directors on September 3, 2025 and signed on its behalf by:



Dr Richard Mason
Director

Apollo AP21 Limited
Registered Number: 13737726

Apollo AP21 Limited

Statement of Changes in Equity

for the year ended 31 December

	Share capital \$'000	Share premium \$'000	Retained earnings \$'000	Total \$'000
Balance at 31 December 2022	—	—	(1,006)	(1,006)
Loss for the period			(974)	(974)
Total comprehensive loss for the period	—	—	(974)	(974)
Balance at 31 December 2023	—	—	(1,980)	(1,980)
Loss for the period			(404)	(404)
Total comprehensive loss for the period	—	—	(404)	(404)
Balance at 31 December 2024	—	—	(2,384)	(2,384)

The notes on pages 8 - 11 are an integral part of these financial statements.

Apollo AP21 Limited

Notes to the Financial Statements

for the year ended 31 December 2024

1. General information

Apollo AP21 Limited is a private limited company and is incorporated and domiciled in the UK. The address of its registered office is 3rd Floor, 22 Station Road, Cambridge, CB1 2JD.

The Company is a special purpose vehicle ("SPV") advancing a potentially transformative therapeutic program into clinical development and ultimately into patient treatment.

The financial statements are prepared in US dollars, which is the presentational currency of the Company. Monetary amounts in these financial statements are rounded to the nearest \$'000. The functional currency of the Company is US dollars (\$).

2. Significant accounting policies

2.1 Basis of preparation of financial statements

The financial statements have been prepared under the historical cost convention unless otherwise specified within these accounting policies and in accordance with Financial Reporting Standard 101, 'Reduced Disclosure Framework' and the Companies Act 2006.

As permitted by FRS 101, the Company has taken advantage of the disclosure exemptions available under that standard in relation to financial instruments, capital management, presentation of a cash flow statement, share based payments, fair value measurements, standards not yet effective, related party transactions with other wholly-owned members of the group and key management personnel compensation. Equivalent disclosures are, where required, given in the group accounts of Apollo Therapeutics Group Limited.

The preparation of financial statements in compliance with FRS 101 requires the use of certain critical accounting estimates. It also requires Company management to exercise judgement in applying the Company's accounting policies (see note 3).

The following principal accounting policies have been applied:

2.2 Going concern

Apollo AP21 Limited is reliant on funding received from its parent company Apollo Therapeutics Group Limited ("the Group") and has no other external source of income. Apollo AP21 Limited is an SPV of its direct parent Apollo Therapeutics Limited which is the main treasury entity of the Group and accordingly the directors have assessed the Group's ability to continue to fund Apollo Therapeutics Limited, and in turn Apollo AP21 Limited.

The directors believe that the Group will have sufficient funding to continue its operations for at least twelve months from the date of approval of these financial statements. Accordingly, the accounts have been prepared on the going concern basis.

The Group expects, over the coming years, to finance its operations through a combination of cash on hand and private or public equity financings. The Groups failure to raise capital as and when needed would have a negative effect on our financial condition and our ability to execute our business strategy. Based on the Directors' current forecasts and plans, the directors have considered scenarios where costs within the directors' control can be delayed or deferred to ensure that the Group has sufficient funding to continue its operations for a period of at least 12 months from the date of approval of these financial statements. The base case is built on the assumption of nil revenue generation.

2.3 Foreign currencies

Transactions in currencies other than the entity's functional currency (foreign currencies) are recognised at the rates of exchange prevailing on the dates of the transactions, with differences recorded in the income statement. At each reporting date, monetary assets and liabilities that are denominated in foreign currencies are retranslated at the rates prevailing at that date.

Apollo AP21 Limited

Notes to the Financial Statements (continued)

for the year ended 31 December 2024

2.4 Taxation

The tax expense represents the sum of the tax currently payable and deferred tax.

Current tax

The tax currently payable is based on taxable profit for the year. Taxable profit differs from net profit as reported in the income statement because it excludes items of income or expense that are taxable or deductible in other years and it further excludes items that are never taxable or deductible. The Company's liability for current tax is calculated using tax rates that have been enacted or substantively enacted by the reporting date.

The benefit of research and development is recognised under the UK's Research and Development Expenditure Credit ("RDEC") scheme. The benefit is recorded as income included in profit before tax, netted against research and development expenses, as the RDEC is of the nature of a government grant.

Deferred tax

Deferred tax is the tax expected to be payable or recoverable on differences between the carrying amounts of assets and liabilities in the financial statements and the corresponding tax bases used in the computation of taxable profit and is accounted for using the balance sheet liability method. Deferred tax liabilities are recognised for all taxable temporary differences and deferred tax assets are recognised to the extent that it is probable that taxable profits will be available against which deductible temporary differences can be utilised. However, such assets and liabilities are not recognised if the temporary difference arises from the initial recognition of goodwill or from the initial recognition (other than in a business combination) of other assets and liabilities in a transaction that affects neither the taxable profit nor the accounting profit.

Deferred tax is calculated at the tax rates that are expected to apply in the period when the liability is settled or the asset is realised based on tax laws and rates that have been enacted or substantively enacted at the reporting date. Deferred tax is charged or credited in the income statement, except when it relates to items charged or credited in other comprehensive income, in which case the deferred tax is also dealt with in other comprehensive income.

Deferred tax assets and liabilities are offset when there is a legally enforceable right to set off current tax assets against current tax liabilities and when they relate to income taxes levied by the same taxation authority and the Company intends to settle its current tax assets and liabilities on a net basis.

3. Critical accounting judgements and key sources of estimation uncertainty

In the application of the Company's accounting policies, the directors are required to make judgements, estimates and assumptions about the carrying amounts of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates.

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised.

4. Operating loss

Operating loss has been arrived at after charging:

	2024 \$'000	2023 \$'000
Research and development expenditure	373	952

5. Staff costs and directors' remuneration

The Directors remuneration for services to the Company during the period was born by Apollo Therapeutics Limited, the Company's immediate parent entity.

The Company had no other employees during the year.

Apollo AP21 Limited

Notes to the Financial Statements (continued)

for the year ended 31 December 2024

6. Taxation

	2024 \$'000	2023 \$'000
Corporation tax:		
Current year	—	—
	—	—
Deferred tax:		
Origination and reversal of timing differences	25	8
Adjustment in respect of prior years	(1)	—
Total tax charge	24	8

Corporation tax is calculated at 25.00% (2023: 23.52%) of the estimated taxable loss for the year.

The tax charge for each year can be reconciled to the loss per statement of comprehensive income as follows:

	2024 \$'000	2023 \$'000
Loss before tax	(380)	(966)
Tax at the UK corporation tax rate of 25.00% (2023: 23.52%)	(95)	(227)
Adjustments in respect of prior years	(1)	—
Movement in unrecognised deferred tax	120	235
Tax charge for the year	24	8

Included in the 'movement in unrecognised deferred tax' above are R&D expenditure credit Step 2 and 3 restrictions not recognised amounting to \$26k (2023: \$8k). These may be carried forward to offset future tax liabilities but are not recognised given the uncertainty about the Company's ability to offset credits in future periods. The Company also has UK unused tax losses amounting to \$1.8m (2023: \$1,400k). A deferred tax asset as at 31 December 2024 amounting to \$449k (2023: \$354k) has not been recognised in these financial statements as it is unlikely that the Company will generate taxable profits in the foreseeable future to enable the losses to be utilised. Deferred tax is calculated using tax rates that are expected to apply in the period when the liability or asset is expected to be realised based on rates enacted or substantively enacted by the reporting date.

7. Trade and other receivables

	2024 \$'000	2023 \$'000
Amount owed by group undertakings	292	292
Prepayments	—	9
	292	301

Apollo AP21 Limited

Notes to the Financial Statements (continued)

for the year ended 31 December 2024

8. Trade and other payables

	2024 \$'000	2023 \$'000
Amounts falling due within one year:		
Amounts owed to group undertakings	2,688	2,197
Accruals	21	112
	2,709	2,309

9. Share capital

	No.	Amount paid (\$)	2024 \$'000
Allotted share capital			
Ordinary shares issued on incorporation	1	0.01	—
Total	1	0.01	—

	No.	Nominal value (£)	2024 \$'000
Allotted, called up and fully paid Ordinary shares	1	0.01	—

10. Reserves

Retained earnings

Includes all current retained profits and losses.

11. Related parties

The company is exempt from disclosing related party transactions with other companies that are wholly owned within the Group.

There are no other related party transactions.

12. Controlling party

The ultimate parent undertaking of this company is Apollo Therapeutics Group Limited, which is incorporated in England and Wales. The only group undertaking for which consolidated accounts are prepared is that headed by Apollo Therapeutics Group Limited.

The ultimate controlling party of Apollo Therapeutics Group Limited is Patient Square Equity Advisors, LP.

13. Post balance sheet events

There are no subsequent events which require disclosure up to the date that the financial statements were approved on September 3, 2025.